CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of acute leukemias.
  
  OVERVIEW OF ACTIVITY
  The pace of oncology drug development has accelerated in recent years to previously unmatched levels. Fueled by an increased understanding of the biologic underpinnings of tumor development and progression, clinical research platforms largely focused on evaluating the potential benefits of novel targeted therapeutics possessing unique mechanisms of action and safety profiles have led to improved outcomes in myriad large and rigorous clinical trials across many different tumor types. The successes yielded by this rational approach to the design and evaluation of new therapies have in turn provided oncology healthcare professionals and patients with many additional beneficial FDA-endorsed treatment options. Of interest, although this rapid emergence of new agents appears to be prevalent in many different corners of oncology, recent advancements in the field of acute leukemias are particularly pronounced.
  
  Although medical oncologists have been routinely responsible for counseling patients with regard to therapeutic decision-making, oncology nurses play an integral role in the successful delivery of systemic anticancer therapy and the preservation of patient physical and psychosocial well-being. These video proceedings from the fifth part of a 6-part integrated CNE curriculum originally held at the 2018 ONS Annual Congress feature discussions with leading hematologic oncology investigators and their nursing counterparts regarding actual patient cases and recent clinical research findings affecting the optimal therapeutic and supportive care for each patient scenario.
  
  PURPOSE STATEMENT
  By providing information on the latest research developments in the context of expert perspectives, this CNE activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with acute leukemias.
  
  LEARNING OBJECTIVES

  • Assess available research evidence with approved and emerging FLT3 inhibitors, and use this information to guide clinical care and protocol opportunities for appropriate patients with acute myelogenous leukemia (AML).
  • Develop an understanding of the mechanism of action, available data and current and potential role of available and investigational IDH1/2 inhibitors for patients with relapsed/refractory AML and IDH1/2 mutations.
  • Recognize the recent FDA approval of CPX-351 for newly diagnosed therapy-related AML or AML with myelodysplasia-related changes, and discern how this agent can be optimally integrated into nonresearch care algorithms for these patients.
  • Apply the results of clinical research on existing (CAR-T therapy, blinatumomab, inotuzumab ozogamicin) and emerging agents to optimize the clinical and supportive care of patients with newly diagnosed and recurrent acute lymphocytic leukemia.
  • Educate patients about the side effects associated with existing and recently approved therapies, and provide preventive strategies to reduce or ameliorate these toxicities.

  ACCREDITATION STATEMENT
  Research To Practice (RTP) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.
  
  CREDIT DESIGNATION STATEMENT
  CNE credit is no longer available for this issue
  
  ONCOLOGY NURSING CERTIFICATION CORPORATION (ONCC)/INDIVIDUAL LEARNING NEEDS ASSESSMENT (ILNA) CERTIFICATION INFORMATION
  CNE credit is no longer available for this issue
  
  FOR SUCCESSFUL COMPLETION
  This is a video CNE program.
  CNE credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  RTP is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CNE activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:
  
  Bernadette Cuello, MSN, NP-C, AOCNP
  Nurse Practitioner, Outpatient Leukemia Service
  Memorial Sloan Kettering Cancer Center
  New York, New York
  
  No relevant conflicts of interest to disclose.
  
  Eytan M Stein, MD
  Hematologist and Medical Oncologist
  Assistant Attending Physician
  Leukemia Service
  Department of Medicine
  Memorial Sloan Kettering Cancer Center
  New York, New York
  
  Advisory Committee: Celgene Corporation, Novartis.
  
  Wendy Stock, MD
  Anjuli Seth Nayak Professor of Leukemia Research
  Director, Leukemia Program
  The University of Chicago Medicine
  Chicago, Illinois
  
  Advisory Committee: Amgen Inc, Pfizer Inc; Contracted Research: Celgene Corporation, Gilead Sciences Inc.
  
  Lauren Ziskind, APN, NP-C, OCN
  Nurse Practitioner, Adult Leukemia Program
  The University of Chicago
  Chicago, Illinois
  
  Advisory Committee: Pfizer Inc; Speakers Bureau: Incyte Corporation, Pharmacyclics LLC, an AbbVie Company.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME/CNE activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Medivation Inc, a Pfizer Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology and Tokai Pharmaceuticals Inc.
  
  RESEARCH TO PRACTICE CME/CNE PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from AbbVie Inc, Agios Pharmaceuticals Inc, Amgen Inc, Astellas Pharma Global Development Inc, Celgene Corporation and Jazz Pharmaceuticals Inc.
  
  Hardware/Software Requirements:
  A high-speed Internet connection
  A monitor set to 1280 x 1024 pixels or more
  Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
  Adobe Flash Player 27 plug-in or later
  Adobe Acrobat Reader
  (Optional) Sound card and speakers for audio
  
  Last review date: July 2018
  Expiration date: July 2019
  
  There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.